GENTA INCORPORATED /DE/
4, 1998-01-12
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: GENTA INCORPORATED /DE/, 4, 1998-01-12
Next: PROVIDENTMUTUAL VARIABLE ANNUITY SEPARATE ACCOUNT, 497, 1998-01-12



UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
( ) Check this box if no longer subject to Section 16.
Form 4 or Form 5 obligations may continue. See Instructions 1(b).
1. Name and Address of Reporting Person
   Rosenwald, Lindsay A.
   787 Seventh Avenue
   48th Floor
   New York, NY  10019
2. Issuer Name and Ticker or Trading Symbol
   GENTA INCORPORATED /DE/
   GNTA
3. IRS or Social Security Number of Reporting Person (Voluntary)
   
4. Statement for Month/Year
   12/29/97
5. If Amendment, Date of Original (Month/Year)
   
6. Relationship of Reporting Person(s) to Issuer (Check all applicable)
   ( ) Director (X) 10% Owner ( ) Officer (give title below) ( ) Other
   (specify below)
   
7. Individual or Joint/Group Filing (Check Applicable Line)
   ( ) Form filed by One Reporting Person
   (X) Form filed by More than One Reporting Person
<TABLE>
<CAPTION>
___________________________________________________________________________________________________________________________________
 Table I -- Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned                                                 |
___________________________________________________________________________________________________________________________________|
1. Title of Security       |2.    |3.    |4.Securities Acquired (A)         |5.Amount of        |6.Dir |7.Nature of Indirect       |
                           | Transaction |  or Disposed of (D)              |  Securities       |ect   |  Beneficial Ownership     |
                           |      |      |                                  |  Beneficially     |(D)or |                           |
                           |      |    | |                  | A/|           |  Owned at         |Indir |                           |
                           | Date |Code|V|    Amount        | D |    Price  |  End of Month     |ect(I)|                           |
___________________________________________________________________________________________________________________________________|
<S>                        <C>    <C>  <C><C>               <C> <C>         <C>                 <C>    <C>
___________________________________________________________________________________________________________________________________|
<CAPTION>
___________________________________________________________________________________________________________________________________
 Table II -- Derivative Securitites Acquired, Disposed of, or Beneficially Owned                                                   |
___________________________________________________________________________________________________________________________________|
1.Title of Derivative |2.Con-  |3.   |4.    |5.Number of De |6.Date Exer|7.Title and Amount  |8.Price|9.Number    |10.|11.Nature of|
  Security            |version |Transaction | rivative Secu |cisable and|  of Underlying     |of Deri|of Deriva   |Dir|Indirect    |
                      |or Exer |     |      | rities Acqui  |Expiration |  Securities        |vative |tive        |ect|Beneficial  |
                      |cise    |     |      | red(A) or Dis |Date(Month/|                    |Secu   |Securities  |(D)|Ownership   |
                      |Price of|     |      | posed of(D)   |Day/Year)  |                    |rity   |Benefi      |or |            |
                      |Deriva- |     |      |               |Date |Expir|                    |       |ficially    |Ind|            |
                      |tive    |     |      |           | A/|Exer-|ation|   Title and Number |       |Owned at    |ire|            |
                      |Secu-   |     |    | |           | D |cisa-|Date |   of Shares        |       |End of      |ct |            |
                      |rity    |Date |Code|V|  Amount   |   |ble  |     |                    |       |Month       |(I)|            |
___________________________________________________________________________________________________________________________________|
<S>                   <C>      <C>   <C>  <C><C>        <C> <C>   <C>   <C>          <C>     <C>     <C>          <C> <C>
Series D Convertible P|$0.94375|12/29|J(2)| |25,833(3)  |A   |12/31|N/A  |Common Stock|2,737,2|(2)(3) |25,833      |D(2|           |
referred Stock(1)     |        |/97  |(3) | |40,395(3)  |D   |/97  |     |            |72     |       |            |)  |           |
- -----------------------------------------------------------------------------------------------------------------------------------|
Class D Warrants(1)   |$0.94375|12/29|J(2)| |129,163(3) |A  |12/31|6/30/|Common Stock|129,163 |(2)(3) |129,163     |D(2|           |
                      |        |/97  |(3) | |201,975(2) |D  |/97  |02   |            |        |       |            |)  |           |
- -----------------------------------------------------------------------------------------------------------------------------------|
                      |        |     |    | |           |   |     |     |            |       |       |            |   |            |
___________________________________________________________________________________________________________________________________|
</TABLE>
Explanation of Responses:
(1)  The Series D Preferred  Stock and Class D Warrants are  components of units
     ("Units")  issuable upon exercise of warrants  ("Unit  Purchase  Warrants")
     exercisable from December 31, 1997 to June 30, 2002, at an initial exercise
     price  of  $110,000  per  Unit.   Lindsay  A.  Rosenwald,   may  be  deemed
     beneficially  to own,  and  Paramount  Capital  Inc.  may be deemed to have
     disposed of beneficial  ownership of, Unit Purchase Warrants to purchase an
     aggregate of 25.83261 and 40.395  Units, respectively. Each Unit  consists,
     initially,  of (i) 1,000 shares of Series D Preferred  Stock of the Issuer,
     par value  $0.001 per  share,  and (ii) 5,000  Class D  Warrants.  The Unit
     Purchase Warrants contain certain anti-dilution adjustments.
(2)  On December 29, 1997,  Paramount  Capital Inc.  designated  recipients (the
     "Paramount Warrant Designees") of the Unit Purchase Warrants.
(3)  Dr. Rosenwald was among the Paramount  Warrant  Designees and received such
     Unit Purchase Warrants in connection with a private placement of securities
     of the Issuer of which Paramount Capital, Inc. acted as placement agent.

SIGNATURE OF REPORTING PERSON
/s/Lindsay A. Rosenwald, M.D.
- ---------------------------------
Lindsay A. Rosenwald, M.D., 
Individually, and as President of
Paramount Capital, Inc.
DATE
1/9/98

**   Intentional misstatements or omissions of facts constitute Federal Criminal
     Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note:   File three copies of this Form, one of which must be manually signed.
        If space provided is insufficient, see Instruction 6 for procedure.


Potential persons who are to respond to the collection of information  contained
in this form are not  required to respond  unless the form  displays a currently
valid OMB Number.
<PAGE>

                                  Attachment A


     Reporting Persons:   Lindsay A. Rosenwald, M.D. (the designated filer); and
                          Paramount Capital, Inc.
                          787 Seventh Avenue, 48th Floor
                          New York, NY 10019

     Issuer:              Genta Incorporated (GNTA)

     Statement For:       December / 1997

     Lindsay A.  Rosenwald,  M.D.,  the  President and sole  shareholder  of
Paramount Capital, Inc., is also the President and sole shareholder of Paramount
Capital Asset Management,  Inc. ("Paramount").  Paramount is the General Partner
of the Aries  Domestic  Fund,  L.P. (the  "Partnership")  and also serves as the
Investment Manager to The Aries Trust (the "Trust"), a Cayman Islands trust. The
Partnership  and the Trust each owns  securities  of the Issuer.  The  Reporting
Persons disclaim beneficial  ownership of the securities held by the Partnership
and the Trust, except to the extent of their pecuniary interest therein, if any.

     Paramount   Capital,   Inc.  is  no longer   subject  to  Section 16 of the
Securities Exchange Act of 1934, as amended.



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission